Rasagiline (Azilect) is a selective MAO-B inhibitor drug that provides symptomatic benefits in PD treatment and has been found to exert neuroprotective effects in preclinical cellular and animal models of ischemic stroke. The gene discussed is MAOB; the disease is ischemic stroke.